1795 — Lotus Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- TWD71.42bn
- TWD79.24bn
- TWD16.96bn
- 73
- 32
- 38
- 43
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9,611 | 10,729 | 12,649 | 14,633 | 16,958 |
Cost of Revenue | |||||
Gross Profit | 4,422 | 4,597 | 5,640 | 7,806 | 9,384 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8,411 | 9,154 | 10,397 | 10,538 | 12,159 |
Operating Profit | 1,200 | 1,575 | 2,252 | 4,095 | 4,799 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 977 | 1,304 | 1,870 | 3,940 | 5,103 |
Provision for Income Taxes | |||||
Net Income After Taxes | 767 | 1,030 | 1,403 | 3,021 | 4,106 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 663 | 1,027 | 1,403 | 3,021 | 4,106 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 663 | 1,027 | 1,403 | 3,021 | 4,106 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.46 | 4.77 | 6.29 | 12 | 16.6 |
Dividends per Share |